Fierce Pharma
FEBRUARY 21, 2024
On the heels of a turbulent 2023 in which Novavax’s very existence was at stake, the beleaguered vaccine maker has new reason to be optimistic about the future. Novavax has reached a settlement with Gavi, the Vaccine Alliance ending arbitration tied to a 2021 advance purchase agreement around its prototype COVID-19 vaccine NVX-CoV2373.
STAT
SEPTEMBER 26, 2023
The latest rollout of Covid-19 vaccines has been messy, with people facing more challenges getting one of the updated shots than they may have experienced since the frantic start of the very first vaccination campaign in late 2020 and the first half of 2021.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MARCH 4, 2021
UK chancellor Rishi Sunak has announced a budget loaded with initiatives designed to kick-start the UK’s economy as it recovers from the coronavirus pandemic, with vaccine development, pharma and life sciences playing a key role. The post Budget 2021: Sunak focuses on vaccine development to restart economy appeared first on.
STAT
JANUARY 12, 2023
kindergartners who’ve received standard childhood vaccines took a small but notable dip into the 2021-2022 school year, health officials said Thursday, amid disruptions related to Covid-19 and fears that anti-vaccine sentiment stirred up by the pandemic could be spreading to other shots. The percentage of U.S.
Fierce Pharma
NOVEMBER 28, 2023
As the pandemic eased earlier this year, officials in Poland became vocal critics of the financial obligations laid down by Pfizer’s large vaccine supply pact with the European Union. | Now, months after the country asked for a reprieve from the costs imposed by the 2021 agreement, Pfizer is targeting Poland in court.
STAT
OCTOBER 2, 2023
Last month, the first volunteer was injected with an HIV vaccine he spent over 20 years designing. The last shot they tested, in 2021, didn’t do much of anything, and the 66-year-old worries that if this fails, he might not get another chance to redesign it. It’s prototype No.
European Pharmaceutical Review
MARCH 14, 2024
Overall, the goal of expanded facility is to strengthen [SK biosciences] manufacturing capabilities for global supply [of the pneumococcal conjugate vaccine candidate GBP410]” SK bioscience has announced its manufacturing plant L HOUSE, in Andong, Gyeongsangbuk-do, South Korea, is set to have a facility expansion.
Expert insights. Personalized for you.
121 
Let's personalize your content